Study #2015-0212
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
MD Anderson Study Status
Not Accepting
Treatment Agent
Ponatinib
Description
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Leukemia, Chronic, Chronic Phase
Study phase:
Phase II
Physician name:
Koji Sasaki
Department:
Leukemia
For general questions about clinical trials:
1-877-839-0558
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.